Dr. Sarah Galadriel Boles, MD

Dr. Boles practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Boles' NPI, 1245391242, was assigned on December 13, 2006. Dr. Boles graduated from The Johns Hopkins University School of Medicine in 2001. Dr. Boles holds California license A82562.

Dr. Boles' primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Boles' primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Boles is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Boles to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Boles practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Boles' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Boles is board certified in medical oncology by the American Board of Internal Medicine. Dr. Boles is licensed in California.

Dmand AI lists breast cancer among the conditions Dr. Boles treats.

CMS data shows 475 Medicare services from Dr. Boles across 3 procedure codes in 2024, for 131 Medicare patients. Medicare paid $29,203 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 131 Medicare patients who saw Dr. Boles in 2024. The largest group is 65 to 74, with 59 patients. 64% of them have cancer, and 63% have high blood pressure. 26% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Boles' median patient age at 60, with 79% women.

In 2024, Dr. Boles wrote 350 Medicare Part D claims for 57 patients. 68% of them were for generic drugs. CMS names the drug for 238 of them, across 14 drugs with 11 or more claims each, at $978,669 in total drug cost. In 2023, CMS named 112 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Boles for performance year 2024, reported as part of a group. Dr. Boles accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Boles as offering telehealth.

Dmand AI links 19 papers to Dr. Boles, published from 2014 to 2024. 2015 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Sarcoma and Biomarkers, Tumor. Dr. Boles has published most often in J Natl Compr Canc Netw. Dr. Boles' most frequent co-authors are Robert S. Benjamin, MD, Kristen Nooshin Ganjoo, MD and Martin J. Heslin, MD.

Dmand AI links Dr. Boles to 2 clinical trials. Conditions studied include Histiocytoma, Triple Negative Breast Neoplasms and Histiocytoma, Malignant Fibrous. Open Payments lists research payments to Dr. Boles that name 1 trial.

CMS Open Payments shows 7 general payments to Dr. Boles from 5 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Tempus AI, Inc paid the most, $87. It also lists 1 research payment totaling $127 in 2016, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Boles, most recently CMS Stage 1 EHR in 2013.

Dr. Boles graduated from The Johns Hopkins University School of Medicine in 2001.

Dr. Boles is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.